StockData
Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc. (LXRX) stock

LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.72−0.06 (-3.37%)

Close on Nov 18, 2026Market cap $765.32MP/E –Yield –

Lexicon Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Lexicon Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$54.50M. For fiscal 2025 it was -$48.91M. The highest annual figure on record is $141.45M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$48.91M–
FY2024Dec 31, 2024-$197.12M–
FY2023Dec 31, 2023-$171.75M–
FY2022Dec 31, 2022-$100.76M–
FY2021Dec 31, 2021-$87.09M–
FY2020Dec 31, 2020-$47.80M-133.8%
FY2019Dec 31, 2019$141.45M–
FY2018Dec 31, 2018-$103.28M–
FY2017Dec 31, 2017-$130.62M–
FY2016Dec 31, 2016-$127.17M-8762.9%
FY2015Dec 31, 2015$1.47M–
FY2014Dec 31, 2014-$100.37M–
FY2013Dec 31, 2013-$102.37M–
FY2012Dec 31, 2012-$108.42M–
FY2011Dec 31, 2011-$114.10M–
FY2010Dec 31, 2010-$95.72M–
FY2009Dec 31, 2009-$89.96M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$26.54M-810.4%
Q1 FY2026Mar 31, 2026-$996.00K–
Q4 FY2025Dec 31, 2025-$14.78M–
Q3 FY2025Sep 30, 2025-$12.19M–
Q2 FY2025Jun 30, 2025$3.74M–
Q1 FY2025Mar 31, 2025-$25.68M–
Q4 FY2024Dec 31, 2024-$32.74M–
Q3 FY2024Sep 30, 2024-$63.69M–
Q2 FY2024Jun 30, 2024-$55.35M–
Q1 FY2024Mar 31, 2024-$45.33M–
Q4 FY2023Dec 31, 2023-$46.74M–
Q3 FY2023Sep 30, 2023-$49.63M–
Q2 FY2023Jun 30, 2023-$44.24M–
Q1 FY2023Mar 31, 2023-$31.14M–
Q4 FY2022Dec 31, 2022-$30.28M–
Q3 FY2022Sep 30, 2022-$23.10M–
Q2 FY2022Jun 30, 2022-$24.01M–
Q1 FY2022Mar 31, 2022-$23.38M–
Q4 FY2021Dec 31, 2021-$25.33M–
Q3 FY2021Sep 30, 2021-$22.96M-126.5%
Q2 FY2021Jun 30, 2021-$17.96M–
Q1 FY2021Mar 31, 2021-$20.84M–
Q4 FY2020Dec 31, 2020-$7.46M–
Q3 FY2020Sep 30, 2020$86.68M-61.4%
Q2 FY2020Jun 30, 2020-$64.58M–
Q1 FY2020Mar 31, 2020-$62.44M–
Q4 FY2019Dec 31, 2019-$47.22M–
Q3 FY2019Sep 30, 2019$224.68M–
Q2 FY2019Jun 30, 2019-$18.55M–
Q1 FY2019Mar 31, 2019-$17.47M–
Q4 FY2018Dec 31, 2018-$12.37M–
Q3 FY2018Sep 30, 2018-$22.93M–
Q2 FY2018Jun 30, 2018-$30.27M–
Q1 FY2018Mar 31, 2018-$37.71M–
Q4 FY2017Dec 31, 2017-$29.02M–
Q3 FY2017Sep 30, 2017-$28.61M–
Q2 FY2017Jun 30, 2017-$33.49M–
Q1 FY2017Mar 31, 2017-$39.51M–
Q4 FY2016Dec 31, 2016-$31.33M–
Q3 FY2016Sep 30, 2016-$34.93M–

More Lexicon Pharmaceuticals figures

See a number that looks wrong?